
Septerna Inc (SEPN) Stock Forecast & Price Target
Septerna Inc (SEPN) Analyst Ratings
Bulls say
Septerna is rapidly developing its pipeline of product candidates, with a focus on treating patients in three key therapeutic areas. The company is making significant progress in its clinical development, with plans to initiate a Phase 2b trial for its lead candidate SEP-631 in second half of 2026. In addition, Septerna has multiple other programs in various phases of development and is also advancing its oral small molecule PTH1R agonist program for hypoparathyroidism. The company has a strong partnership with Novo Nordisk in obesity and is utilizing its proprietary Native Complex Platform to develop treatments for various diseases. With a discounted cash flow-based valuation and conservative assumptions, Septerna has a price objective of $35 per share. However, potential risks such as delays in clinical development and partnership risks should be considered. Upcoming catalysts include the company's plans to initiate a Phase 1 trial for its PTH1R agonist candidate, as well as the release of clinical data for SEP-631 in the first half of 2026.
Bears say
Septerna is a clinical-stage biotechnology company that has a promising pipeline of product candidates in three therapeutic areas; however, its current enterprise value of only $430M does not accurately reflect the potential value of its obesity candidates, as shown by the recent M&A battle between Novo and Pfizer. Additionally, Septerna is making progress in advancing its lead compounds in its TSHR-NAM program and continues to explore new therapeutic areas through its partnership with Novo. Despite these positive developments, the stock still faces significant risk and uncertainty in preclinical and clinical trials, making it a risky investment.
This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.
Septerna Inc (SEPN) Analyst Forecast & Price Prediction
Start investing in Septerna Inc (SEPN)
Order type
Buy in
Order amount
Est. shares
0 shares